Equillium Inc at Jefferies Healthcare Conference (Virtual) Transcript
Good afternoon. This is Bruce Steel the Chief Executive Officer of Equillium, and I'm joined with my colleague, Krishna Polu. We're very happy to be here with you today. I just wanted to see if Biren is on the call now, or if we are on our own now. Okay, sounds like we are on our own.
Well we appreciate you taking time today to get the update on Equillium and we hope everybody is doing well despite the COVID pandemic, which is obviously been front and center to most of us over the last few months.
We have our standard safe harbor statement in terms of forward looking statements. Equillium as some of you may know and if you are new to the story, we're very pleased to have this opportunity to introduce you to the company.
We started about three years ago around a very interesting lead asset, itolizumab, that we are developing for a range of autoimmune and inflammatory disorders of high unmet medical need. We're based in La Jolla, California. We also have presence in South San Francisco. Itolizumab is currently in development for three
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |